Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427145 | 0.99 | HPGD (0.57) | HPGDCYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL1279081 | 0.92 | HPGD (0.61) | HPGDCYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL1279329 | 0.86 | MEN1 (0.60) | HPGDCYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL17080774 | 0.80 | MEN1 (0.64) | HPGDCYP1A2CYP2C19MAPTSMN1; SMN2 | |
| SCHEMBL11193618 | 0.78 | MAPT (0.55) | HPGDCYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL3425734 | 0.78 | BCHE (0.71) | ALDH1A1MEN1KMT2AATMMAPK1 | |
| SCHEMBL16517050 | 0.78 | LTA4H (0.63) | — | |
| SCHEMBL4259707 | 0.77 | MEN1 (0.56) | CYP1A2CYP2C19SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25807952 | 0.76 | S1PR2 (0.62) | HPGDS1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL8497081 | 0.76 | MEN1 (0.62) | HPGDMAPTSMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649005-B2 | (R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine; monoamine oxidase inhibitors; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-19 | — | — | US | claimed |
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | claimed |
| EP-1673356-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | Newron Pharmaceuticals S.p.A. (IT) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040138-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-05-06 | — | — | WO | claimed |
| EP-1524267-A1 | Substituted benzylaminoalkylene heterocycles | Newron Pharmaceuticals S.p.A. (IT) | 2005-04-20 | — | — | EP | claimed |
| US-7649005-B2 | (R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine; monoamine oxidase inhibitors; neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-19 | — | — | US | disclosed |
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
| EP-1673356-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | Newron Pharmaceuticals S.p.A. (IT) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040138-A1 | SUBSTITUTED BENZYLAMINOALKYLENE HETEROCYCLES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-05-06 | — | — | WO | disclosed |
| EP-1524267-A1 | Substituted benzylaminoalkylene heterocycles | Newron Pharmaceuticals S.p.A. (IT) | 2005-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135496-A1 | Substituted benzylaminoalkylene heterocycles | HTR7, MAOB, CYP2A7 | HPGD 1283/4885CYP1A2 124/4885CYP2C9 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.